BSc (Hons), BM (Hons), MRCP, PhD
Homepage
Latest Videos
Latest Videos
Brightcove Home Latest Listing
Breast Cancer
Breast Cancer
Brightcove Cards Listing
Prostate Cancer
Brightcove Cards Listing
Multiple Myeloma
Multiple Myeloma
Brightcove Cards Listing
Popular on MedEnrich
Popular in No name
- Breast Cancer3m 2s
ESR1 Mutation as an emerging clinical biomarker metastatic hormone receptor positive Breast Cancer
Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.
- OncoSpecials50m 57s
Understanding Biosimilars -An Expert Perspective
Biosimilars are biologic medicines that are highly similar to an FDA-approved reference product, with no clinically meaningful differences in terms of safety, purity, and potency.
- Breast Cancer14m 46s
ESMO 2022 Breast Cancer Comprehensive Coverage
View comprehensive coverage of Breast Cancer from ESMO 2022
- Multiple Myeloma11m 40s
How I Treat Relapsed Refractory Multiple Myeloma
Treating relapsed or refractory multiple myeloma (RRMM) can be complex and typically involves a combination of therapies based on the patient's previous treatments, overall health, and specific disease characteristics.
- Multiple Myeloma9m 20s
Integrating Pomalidomide Based Regimens in Multiple Myeloma
Integrating pomalidomide and dexamethasone in the treatment of relapsed or refractory multiple myeloma (RRMM) involves using them as a core regimen, often combined with other agents like bortezomib or monoclonal antibodies for enhanced efficacy.
- Myelodysplastic Syndromes8m 45s
Current Challenges in MDS Diagnosis and Consequences
Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.
- Breast Cancer8m 46s
Expert Perspective - How I Treat Metastatic Her2 Positive Breast Cancer
Anti-HER2 directed therapy remains the cornerstone of care for individuals with HER2-positive metastatic breast cancer (MBC).
- Prostate Cancer49m 18s
Dissecting the biology of advanced prostate cancer
Advanced prostate cancer is characterized by intricate biological changes, including genetic and epigenetic alterations, as well as shifts in cellular metabolism.
- Pharmacy37m 20s
Quality management systems in pharmacy practice
Dr Scott Soefje, PharmD, Mayo Clinic
Provides a perspective “Quality Management Systems in Pharmacy Practice”.
- Breast Cancer11m 28s
ESR1 Mutation in Hormone Receptor Positive Advanced Breast Cancer
ESR1 mutation leads to ligand independent activation of estrogen receptor. ESR1 mutations were first described in 1997 & their role remain underestimated as initial research was focused on primary tumor wherein these mutations were absent.
- 1
ESR1 Mutation as an emerging clinical biomarker...
- 2
Understanding Biosimilars -An Expert Perspective
- 3
ESMO 2022 Breast Cancer Comprehensive Coverage
- 4
How I Treat Relapsed Refractory Multiple Myeloma
- 5
Integrating Pomalidomide Based Regimens in Multiple...
- 6
Current Challenges in MDS Diagnosis and Consequences
- 7
Expert Perspective - How I Treat Metastatic Her2...
- 8
Dissecting the biology of advanced prostate cancer
- 9
Quality management systems in pharmacy practice
- 10
ESR1 Mutation in Hormone Receptor Positive Advanced...
For Pharmacist
For Pharmacist
Brightcove Cards Listing
Webinars
Webinar Cards Listing
Upcoming Webinar
Upcoming Webinar
MedBytes
MedBytes
Medbytes Cards Listing
Notable KOLs
Discover Notable KOLs
M.D., MSCE
M.D.
M.D., MSC
M.D.
M.D.
